• Home
  •  / Nektar Therapeutics

Nektar Therapeutics

OverviewSuggest Edit

Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

TypePublic
Founded1990
HQSan Francisco, USMap
Websitenektar.com
Employee Ratings3.5More
View Jobs (74)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)618(+22%)
Job Openings74
Revenue (FY, 2019)$114.6 M(-90%)
Share Price (May 2020)$23

Key People/Management at Nektar Therapeutics

Jeff Ajer

Jeff Ajer

Director
Howard W. Robin

Howard W. Robin

Director
Kevin Brodbeck

Kevin Brodbeck

Senior Vice President of Manufacturing
R. Scott Greer

R. Scott Greer

Director
Myriam J. Curet

Myriam J. Curet

Director
Gil M. Labrucherie

Gil M. Labrucherie

Chief Operating Officer and Chief Financial Officer
Show more

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Secunderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South, San Francisco
Huntsville, US
1112 Church St NW
Secunderabad, IN
Shamirpet, Secunderabad
Show all (3)

Nektar Therapeutics Financials and Metrics

Nektar Therapeutics Revenue

Embed Graph
View revenue for all periods
Nektar Therapeutics's revenue was reported to be $114.62 m in FY, 2019
USD

Revenue (Q1, 2020)

50.6m

Gross profit (Q1, 2020)

46.8m

Gross profit margin (Q1, 2020), %

92.5%

Net income (Q1, 2020)

(138.7m)

EBIT (Q1, 2020)

(133.6m)

Market capitalization (22-May-2020)

4.1b

Closing stock price (22-May-2020)

23.0

Cash (31-Mar-2020)

227.0m

EV

4.0b
Nektar Therapeutics's current market capitalization is $4.1 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014Y, 2015FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

71.5m81.2m148.9m200.7m230.8m230.8m165.4m307.7m1.2b114.6m

Revenue growth, %

35%15%(28%)

Cost of goods sold

21.9m30.4m38.5m28.5m34.1m34.1m30.2m30.5m24.4m21.4m

Gross profit

49.6m50.8m110.4m172.2m196.7m196.7m135.2m277.2m1.2b93.2m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

11.3m17.3m27.1m17.9m23.7m18.4m23.0m33.9m60.9m19.8m28.5m132.9m108.8m22.7m60.0m58.9m32.8m36.3m24.7m34.6m152.9m38.0m1.1b27.8m28.2m23.3m29.2m50.6m

Cost of goods sold

3.3m8.1m5.0m8.7m7.2m7.2m11.7m5.0m12.9m7.9m5.1m9.2m8.4m10.5m6.8m8.9m7.7m7.0m6.1m9.0m5.7m6.6m5.4m5.0m4.9m3.8m

Gross profit

8.0m9.2m22.0m9.2m16.5m11.2m11.3m28.9m48.0m11.9m23.4m123.7m100.4m12.1m53.2m50.0m25.1m29.3m18.6m25.6m147.3m31.4m22.8m18.3m24.3m46.8m

Gross profit Margin, %

71%53%81%51%70%61%49%85%79%60%82%93%92%54%89%85%76%81%75%74%96%83%81%78%83%92%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

15.3m25.4m39.1m12.4m55.6m59.6m4.8m194.9m96.4m

Accounts Receivable

4.9m5.8m2.2m3.6m19.9m5.0m43.2m36.8m

Prepaid Expenses

17.9m13.4m5.2m8.8m9.8m14.9m21.3m15.4m

Inventories

12.7m18.3m13.5m13.0m11.3m11.1m10.7m11.4m12.7m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

22.5m11.6m43.0m148.5m136.2m10.3m28.5m41.4m65.4m32.4m30.7m32.0m129.5m20.9m18.8m72.5m55.7m63.3m23.5m16.1m38.0m34.8m911.1m222.3m106.8m85.4m81.2m227.0m

Accounts Receivable

2.2m8.5m12.9m10.8m11.4m3.9m3.6m6.0m4.6m1.9m3.0m46.1m2.9m3.7m3.0m39.7m27.8m14.2m1.6m4.1m3.3m15.6m35.3m31.9m42.9m37.3m41.2m42.0m

Prepaid Expenses

6.9m7.9m7.6m13.6m9.3m7.0m8.8m6.0m4.8m6.0m4.6m4.7m6.1m8.8m5.2m5.6m5.4m4.0m7.9m7.5m13.3m13.1m34.9m12.5m19.4m13.2m15.2m

Inventories

11.7m9.8m10.7m14.1m14.7m16.8m18.4m20.5m15.1m12.9m14.1m11.7m12.5m10.1m10.4m11.3m10.3m10.8m13.0m11.0m13.7m10.7m11.9m13.3m11.8m13.2m13.7m14.3m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(134.0m)(171.9m)(162.0m)(53.9m)(81.2m)(153.5m)(96.7m)681.3m(440.7m)

Depreciation and Amortization

15.0m14.5m14.3m12.9m12.9m15.4m14.7m10.9m13.2m

Inventories

(5.4m)(5.6m)4.8m500.0k1.6m237.0k383.0k(655.0k)(1.3m)

Accounts Payable

(3.4m)(122.0k)6.2m(6.4m)(412.0k)518.0k2.1m971.0k13.0m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(36.0m)(72.4m)(96.5m)(41.1m)(75.4m)(118.9m)(55.1m)(97.8m)(114.4m)(46.2m)(78.8m)(8.2m)33.8m(18.8m)(27.0m)(19.5m)(68.1m)(111.3m)(63.9m)(123.7m)(62.9m)(95.8m)875.7m779.5m(118.5m)(228.4m)(327.2m)(138.7m)

Depreciation and Amortization

3.9m7.6m11.4m3.5m7.0m10.6m3.6m7.3m10.9m3.3m6.5m9.7m3.0m5.8m9.1m3.7m7.6m11.5m4.0m8.3m12.1m2.5m5.1m7.8m3.1m6.1m9.6m4.5m

Inventories

(4.4m)(2.5m)(3.4m)(1.5m)(2.1m)4.1m(112.0k)(2.2m)3.2m580.0k(659.0k)1.8m441.0k2.8m2.6m96.0k1.1m592.0k(1.9m)101.0k(2.5m)51.0k(1.2m)(2.6m)(397.0k)(1.8m)(2.3m)(1.7m)

Accounts Payable

(2.9m)(3.1m)(4.2m)(1.3m)80.0k(401.0k)1.4m2.6m697.0k(6.1m)(1.8m)(3.7m)2.2m(10.0k)(525.0k)(34.0k)17.0k4.8m4.1m3.2m5.7m6.5m5.8m2.6m5.2m3.5m16.1m2.7m
show all
USDY, 2020

EV/EBIT

-30.2 x

EV/CFO

-51.6 x

Financial Leverage

1.5 x
Show all financial metrics

Nektar Therapeutics Online and Social Media Presence

Nektar Therapeutics's Trends

Embed Graph

Nektar Therapeutics News and Updates

January 25, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
January 13, 2020

Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?

NEW YORK, Jan. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BILI, MSFT, NIO, NKTR, and NVDA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
November 09, 2019

Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO, Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clinical...
October 23, 2019

How Bempegaldesleukin Woes Have Impacted Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company based in San Francisco, is focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain. The stock is down by about 20% over the last month and by almost 50% in the last quarter ...
October 08, 2019

Nektar Therapeutics shares slide 6.3% premarket after Goldman downgrades to sell from buy

Nektar Therapeutics shares slid 6.3% in premarket trade Tuesday, after Goldman Sachs downgraded the stock to sell from buy and said the stock will likely flounder in the near term due to quality issues and a narrower focus for bempegaldesleukin, its treatment for cancer. Analysts led by Paul Choi s…
October 02, 2019

Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentations include...
Show more

Nektar Therapeutics Blogs

February 03, 2020

Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications

Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications Content Import Mon, 02/03/2020 - 08:01 Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempega…
January 10, 2020

Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

SAN FRANCISCO & NEW YORK --(BUSINESS WIRE)--Jan. 10, 2020-- Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new
January 07, 2020

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Content Import Tue, 01/07/2020 - 09:01 Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Confe…
December 17, 2019

Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

SAN FRANCISCO , Dec. 17, 2019 /PRNewswire/ --  Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Myriam J. Curet , M.D., as an independent director to its Board of Directors. Dr. Curet brings three decades of experience working in the healthcare sector and academia, and currently
December 09, 2019

Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

SAN FRANCISCO , Dec. 9, 2019 /PRNewswire/ --  Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255.
December 03, 2019

Nektar Appoints John Northcott as Chief Commercial Officer

SAN FRANCISCO , Dec. 3, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President and Chief Commercial Officer. John will also serve as a member of the Company's Executive Committee
Show more

 Nektar Therapeutics Frequently Asked Questions

  • When was Nektar Therapeutics founded?

    Nektar Therapeutics was founded in 1990.

  • Who are Nektar Therapeutics key executives?

    Nektar Therapeutics's key executives are Jeff Ajer, Howard W. Robin and Kevin Brodbeck.

  • How many employees does Nektar Therapeutics have?

    Nektar Therapeutics has 618 employees.

  • What is Nektar Therapeutics revenue?

    Latest Nektar Therapeutics annual revenue is $114.6 m.

  • What is Nektar Therapeutics revenue per employee?

    Latest Nektar Therapeutics revenue per employee is $185.5 k.

  • Who are Nektar Therapeutics competitors?

    Competitors of Nektar Therapeutics include Progenics Pharmaceuticals, La Jolla Pharmaceutical Company and Exelixis.

  • Where is Nektar Therapeutics headquarters?

    Nektar Therapeutics headquarters is located at 455 Mission Bay Boulevard South, San Francisco, San Francisco.

  • Where are Nektar Therapeutics offices?

    Nektar Therapeutics has offices in San Francisco, Huntsville and Secunderabad.

  • How many offices does Nektar Therapeutics have?

    Nektar Therapeutics has 3 offices.